是时候要求分子放射治疗的剂量测定了吗？
Time to demand dosimetry for molecular radiotherapy?
作者信息
McGowan D R, Guy M J
机构信息
1 Department of Oncology, University of Oxford, Oxford, UK.
出版信息
Br J Radiol. 2015 Mar;88(1047):20140720. doi: 10.1259/bjr.20140720. Epub 2015 Jan 9.
Abstract
Molecular radiotherapy (MRT) has been used clinically for around 75 years. Despite this long history of clinical use, there is no established dosimetry practice for calculating the absorbed dose delivered to tumour targets or to organs at risk. As a result, treatment protocols have often evolved based on experience with relatively small numbers of patients, each receiving a similar administered activity but, potentially, widely varying doses. This is in stark contrast to modern external-beam radiotherapy practice. This commentary describes some of the barriers to MRT dosimetry and gives some opinions on the way forward.
摘要
分子放射治疗（MRT）已在临床上应用了约75年。尽管有如此长的临床应用历史，但目前尚无确定的剂量测定方法来计算传递到肿瘤靶区或危及器官的吸收剂量。因此，治疗方案往往是基于相对少数患者的经验而制定的，每个患者接受的给药活度相似，但潜在剂量却可能差异很大。这与现代外照射放射治疗实践形成了鲜明对比。本评论描述了MRT剂量测定的一些障碍，并对未来的发展方向提出了一些看法。
相似文献
1
Time to demand dosimetry for molecular radiotherapy?
Br J Radiol. 2015 Mar;88(1047):20140720. doi: 10.1259/bjr.20140720. Epub 2015 Jan 9.
2
The contest between internal and external-beam dosimetry: The Zeno's paradox of Achilles and the tortoise.
Phys Med. 2024 Jan;117:103188. doi: 10.1016/j.ejmp.2023.103188. Epub 2023 Dec 2.
3
Dosimetry of clinical neutron and proton beams: an overview of recommendations.
Radiat Prot Dosimetry. 2004;110(1-4):565-72. doi: 10.1093/rpd/nch221.
4
[Outline of standard dosimetry of absorbed dose to water in external beam radiotherapy].
Igaku Butsuri. 2013;33(4):171-8.
5
Radiotherapy quality assurance by individualized in vivo dosimetry: state of the art.
Cancer Radiother. 2009 Jun;13(3):182-9. doi: 10.1016/j.canrad.2009.01.001. Epub 2009 Mar 9.
6
Dosimetry for ion beam radiotherapy.
Phys Med Biol. 2010 Nov 7;55(21):R193-234. doi: 10.1088/0031-9155/55/21/R01. Epub 2010 Oct 15.
7
Clinical perspectives on dosimetry in molecular radiotherapy.
Phys Med. 2023 Oct;114:103154. doi: 10.1016/j.ejmp.2023.103154. Epub 2023 Oct 5.
8
The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1976-88. doi: 10.1007/s00259-014-2824-5. Epub 2014 Jun 11.
9
Multicellular dosimetry for beta-emitting radionuclides: autoradiography, thermoluminescent dosimetry and three-dimensional dose calculations.
Med Phys. 1993 Mar-Apr;20(2 Pt 2):543-50. doi: 10.1118/1.597050.
10
Effect of image registration on 3D absorbed dose calculations in Lu-DOTATOC peptide receptor radionuclide therapy.
Phys Med. 2018 Jan;45:177-185. doi: 10.1016/j.ejmp.2017.11.021. Epub 2018 Jan 8.
引用本文的文献
1
A novel fast strategy to calculate equieffective doses under different dose rate conditions.
Med Phys. 2025 May;52(5):3416-3427. doi: 10.1002/mp.17688. Epub 2025 Feb 15.
2
Cherenkov light emission in molecular radiation therapy of the thyroid and its application to dosimetry.
Biomed Opt Express. 2022 Mar 23;13(4):2431-2449. doi: 10.1364/BOE.448139. eCollection 2022 Apr 1.
3
The internal dosimetry user group position statement on molecular radiotherapy.
Br J Radiol. 2021 Oct 1;94(1126):20210547. doi: 10.1259/bjr.20210547. Epub 2021 Aug 25.
4
Production, Purification, and Applications of a Potential Theranostic Pair: Cobalt-55 and Cobalt-58m.
Diagnostics (Basel). 2021 Jul 9;11(7):1235. doi: 10.3390/diagnostics11071235.
5
Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44.
Chem Sci. 2019 Nov 20;11(2):333-342. doi: 10.1039/c9sc04655k. eCollection 2020 Jan 14.
6
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
BMC Cancer. 2019 Jun 14;19(1):582. doi: 10.1186/s12885-019-5541-4.
7
Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.
Chemistry. 2018 Jan 12;24(3):547-550. doi: 10.1002/chem.201702335. Epub 2017 Sep 14.
8
Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.
J Nucl Med. 2018 Feb;59(2):244-250. doi: 10.2967/jnumed.117.193748. Epub 2017 Jul 26.
9
SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective.
Br J Radiol. 2017 May;90(1073):20160637. doi: 10.1259/bjr.20160637. Epub 2017 Mar 14.
本文引用的文献
1
Five years of molecular radiotherapy growth in the UK: survey results from 2007 to 2012.
Nucl Med Commun. 2015 Aug;36(8):761-5. doi: 10.1097/MNM.0000000000000306.
2
Guidelines for the management of thyroid cancer.
Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122. doi: 10.1111/cen.12515.
3
MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.
J Nucl Med. 2012 Aug;53(8):1310-25. doi: 10.2967/jnumed.111.100123. Epub 2012 Jun 28.
4
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1847-56. doi: 10.1007/s00259-008-0778-1. Epub 2008 Apr 22.
5
Dosimetry in Peptide radionuclide receptor therapy: a review.
J Nucl Med. 2006 Sep;47(9):1467-75.
6
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
J Nucl Med. 2004 Aug;45(8):1366-72.
7
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. doi: 10.1007/s00259-004-1571-4. Epub 2004 May 19.
8
9
Radiation synovectomy revisited.
Eur J Nucl Med. 1993 Nov;20(11):1113-27. doi: 10.1007/BF00173494.
10
Zotero 插件